Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanO2 in Large Vessel Occlusion Ischemic Stroke
NCT05389748Phase 3Unknown
- Sponsor
- NuvOx Therapeutics
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Nanoparticles, Small Molecules
01
Overview
A Phase 3 trial of perflenapent in ischemic stroke, sponsored by NuvOx Therapeutics. Status: unknown.
02
Drugs
perflenapent
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05389748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389748.